FDA approves ramucirumab in hepatocellular carcinoma

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

FDA approved Cyramza (ramucirumab), sponsored by Eli Lilly, as a single agent for hepatocellular carcinoma in patients who have an alpha fetoprotein of ≥ 400 ng/mL and have been previously treated with sorafenib.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

Two years ago, Dan Theodorescu made a discovery that could alter biology textbooks: The Y chromosome, widely considered to be a “functional wasteland,” has functions beyond sex determination—and in fact plays a role in cancer biology. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login